Search

Monte Carlo simulations were used to assess secondary neutron doses received by patients treated with proton therapy for ocular melanoma and craniopharyngioma. MCNPX calculations of out-of-field doses were done for ∼20 different organs considering realistic treatment plans and using computational phantoms representative of an adult male individual. Simulations showed higher secondary neutron doses for intracranial treatments, ∼14 mGy to the salivary glands, when compared with ocular treatments, ∼0.6 mGy to the non-treated eye. This secondary dose increase is mainly due to the higher proton beam energy (178 vs. 75 MeV) as well as to the impact of the different beam parameters (modulation, collimation, field size etc.). Moreover, when compared with published data, the assessed secondary neutron doses showed similar trends, but sometimes with sensitive differences. This confirms secondary neutrons to be directly dependent on beam energy, modulation technique, treatment configuration and methodology. [ABSTRACT FROM AUTHOR]

Following modifications on the beam line at the Orsay Protontherapy Center, dose measurements were performed in order to make a dose map in the treatment rooms and in the delimited radiation-controlled area around beam line. Measurements were performed using tissue-equivalent proportional counters and rem-counters. Analysis of TEPC single event measurements showed that high LET components (>10 keV.µm-1) represent 90 to 99% of total dose equivalent in the treatment rooms and 50 to 90% in the controlled area and quality factors range, respectively between 2 and 15. A fast neutron component was identified in the treatment rooms, where dose equivalent rate varied between few µSv.h-1 to some dozen of mSv.h-1. In high-energy radiation field rem-counters underestimated TEPC values for neutron component. The variation between instruments response according to the location is linked to energetic spectrum variations and instrument characteristics. [ABSTRACT FROM AUTHOR]